Trial Profile
Multicenter, Non-comparative Extension of Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Ponesimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OPTIMUM-LT
- Sponsors Actelion Pharmaceuticals
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 02 Jan 2024 Planned End Date changed from 18 Jan 2024 to 26 Jan 2024.
- 17 Nov 2023 This trial has been completed in Hungary, according to the European Clinical Trials Database record.